Background free amplified single-molecule FISH for in situ and flow cytometric applications

Project Details

Description

Narrative Point mutations in cancers that are indicative of drug sensitivity or resistance are usually detected using methods, such as PCR, that do not provide information about the distribution and the context of transformed cells within healthy tissue. We are developing DNA probes that can identify mRNAs produced by the subtly mutated genes in sections of cancer tissues in a particularly sensitive manner. Our approach would be transformative for the clinical pathology practice, because it will become possible to develop digital maps of classically stained tissue sections in which the information about molecular biomarkers indicative of the success or failure of therapy is overlaid.
StatusFinished
Effective start/end date2/16/181/31/23

Funding

  • National Cancer Institute: $557,328.00
  • National Cancer Institute: $501,595.00
  • National Cancer Institute: $557,328.00
  • National Cancer Institute: $540,608.00
  • National Cancer Institute: $557,328.00

Fingerprint

Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.